SLU-PP-332
SLU-PP-332 - Image 2

SLU-PP-332

Price range: $39.00 through $149.00

For research purposes only. Not for human or animal use & not FDA-approved. By purchasing, you confirm you are 21 or older and qualified researcher.

Quantity Price
4 - 5 $35.10
6 - 9 $32.76
10 + $29.25
Money Back Guarantee Guaranteed Quality Customer Support Fast Shipping
SKU: N/A Categories: , ,

Description

SLU-PP-332

Research-Grade ERR Agonist Peptide/Small Molecule
Tagline: Metabolic & Mitochondrial Research Tool

Product Description

SLU-PP-332 is a synthetic agonist of the Estrogen‑Related Receptor alpha (ERRα) (and related ERRβ/γ) nuclear receptors. It has emerged as a tool in research for exploring mitochondrial biogenesis, energy metabolism, fat oxidation, and “exercise mimetic” pathways. In its 10 mg vial format, SLU-PP-332 is intended for laboratory and in vitro/preclinical research only—not for human use.

For laboratory and scientific research only. Not for human consumption.

Why Researchers Choose SLU-PP-332

  • Targets ERR α/β/γ – key regulators of mitochondrial and oxidative metabolism

  • Mimics physiological adaptations to endurance exercise in preclinical models

  • Supports research into metabolic syndrome, adiposity, insulin sensitivity

  • Useful for mitochondrial function, muscle fiber adaptation, fat oxidation studies

  • Supplied in high-purity form suitable for research protocols

Important Note

For laboratory and scientific research only. Not for human consumption, therapeutic or diagnostic use.

Details

Compound Name SLU-PP-332
Form Lyophilized powder
Intended Research Use Mitochondrial biogenesis, fat oxidation, metabolic regulation
Storage Conditions –20 °C (dry); handle under inert conditions after reconstitution

Research

Research Applications

Metabolic Regulation & Exercise-Mimetic Studies

SLU-PP-332 has been shown in preclinical models to activate ERR pathways, increase mitochondrial biogenesis (via PGC-1α activation), enhance energy expenditure, and promote fatty acid oxidation, mimicking some effects of endurance exercise without physical training.

Fat Oxidation & Adiposity Reduction

Animal studies indicate SLU-PP-332 may reduce adipose mass, increase resting metabolic rate, and improve insulin sensitivity, making it relevant for research into obesity, metabolic syndrome and related pathologies.

Mitochondrial & Cellular Bioenergetics Research

By targeting ERR receptors, SLU-PP-332 is used in research to probe mitochondrial function, oxidative phosphorylation, and the adaptation of skeletal muscle toward more oxidative (fat‐burning) fiber types.

References

  1. Eissa ME. (2025). “SLU-PP-332 AND RELATED ERRα AGONISTS: A FOCUSED MINIREVIEW OF METABOLIC REGULATION AND THERAPEUTIC POTENTIAL.” UJPR.
    https://doi.org/10.22270/ujpr.v10i3.1355

  2. Nasri H. (2024). “New hopes on ‘SLU-PP-332’ as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view.” Journal of Renal Endocrinology.
    https://doi.org/10.34172/jre.2024.25143 

  3. Mahale BM, Girase AM, Mahale M. (2024). “Unlocking the potential: SLU-PP-332 and the future of exercise enhancement and metabolic health.” Research Journal of Science and Technology, 16(4):321-4. https://doi.org/10.52711/2349-2988.2024.00047 

  4. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” (2023). J Pharmacol Exp Ther.
    https://doi.org/10.1124/jpet.123.001733

Mechanism of Action

Mechanism of Action

  • ERRα/β/γ Agonism: Binds to estrogen-related orphan receptors, triggering transcription of genes for mitochondrial biogenesis, oxidative metabolism, and fat oxidation.

  • PGC-1α Activation: Upregulates PGC-1α (co-activator) leading to increased mitochondrial number and function.

  • Fatty Acid Oxidation Enhancement: Upregulates enzymes such as CPT1 and MCAD, enhances fat utilization for energy.

  • Exercise‐Mimetic Adaptation: Induces muscle fiber type shift toward oxidative fibers, increased endurance/mitochondrial density.

  • Energy Expenditure Increase: Elevates resting metabolic rate, thermogenesis and substrate use in preclinical models.

References

  1. Eissa ME. (2025). “SLU-PP-332 AND RELATED ERRα AGONISTS: A FOCUSED MINIREVIEW OF METABOLIC REGULATION AND THERAPEUTIC POTENTIAL.” UJPR.
    https://doi.org/10.22270/ujpr.v10i3.1355

  2. Nasri H. (2024). “New hopes on ‘SLU-PP-332’ as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view.” Journal of Renal Endocrinology.
    https://doi.org/10.34172/jre.2024.25143 

  3. Mahale BM, Girase AM, Mahale M. (2024). “Unlocking the potential: SLU-PP-332 and the future of exercise enhancement and metabolic health.” Research Journal of Science and Technology, 16(4):321-4. https://doi.org/10.52711/2349-2988.2024.00047 

  4. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” (2023). J Pharmacol Exp Ther.
    https://doi.org/10.1124/jpet.123.001733

Certificate of Authenticity

Related products

  • MLT I
  • B12 - 10mg
  • ION-2T
  • GLOW - 70mg